PIOGLITAZONE HYDROCHLORIDE (pioglitazone) by Takeda is action. Approved for type 2 diabetes mellitus in multiple clinical settings, type 2 diabetes mellitus. First approved in 2013.
Drug data last refreshed 18h ago
action. Pioglitazone hydrochloride decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome…
Worked on PIOGLITAZONE HYDROCHLORIDE at Takeda? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants
Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
Effects of Pioglitazone in Calcific Aortic Valve Disease